Two firms scheduled to go before the Oncologic Drugs Advisory panel today took painful financial hits on Friday when FDA reviewers released unfavorable comments about their respective cancer treatments. (BioWorld Today)
Two firms scheduled to go before the Oncologic Drugs Advisory panel today took painful financial hits on Friday when FDA reviewers released unfavorable comments about their respective cancer treatments. (BioWorld Today)
Despite Celgene Corp.'s low expectations regarding Revlimid's ability as a monotherapy in the difficult indication of metastatic malignant melanoma patients who already had failed two lines of therapy, the firm's stock dipped on stopping a Phase III trial in that indication. (BioWorld Today)
